<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Post-transplant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (PTLD) are a well recognised complication of conventional haemopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Reduced intensity HSCT involves intensive immunosuppression to permit engraftment </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty reduced intensity transplants with the FBC (fludarabine 150 mg/m2, busulphan 8 mg/m2, CAMPATH-1H 100 mg) protocol have been performed at our centre, with one confirmed EBV-positive PTLD </plain></SENT>
<SENT sid="3" pm="."><plain>The female recipient developed a perforated viscus day +191 following HSCT from a volunteer unrelated male donor </plain></SENT>
<SENT sid="4" pm="."><plain>A large caecal mass and a retroperitoneal <z:mpath ids='MPATH_612'>abscess</z:mpath> were excised, revealing an EBV-positive diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> confirmed by FISH to be of donor origin </plain></SENT>
<SENT sid="5" pm="."><plain>More experience is required before the risk of PTLD in this setting can be assessed </plain></SENT>
</text></document>